Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy

Launched by YUANLI ZHAO · Aug 30, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at how certain brain changes and iron buildup might be linked to epilepsy caused by cerebral cavernous malformations (CCMs). CCMs are abnormal blood vessels in the brain that can lead to seizures and impact a person's quality of life. The researchers are using a special imaging technique called quantitative susceptibility mapping (QSM) to measure the amount of iron in these malformations. By comparing patients with and without epilepsy, they hope to better understand the factors that contribute to seizures and improve treatment options for those affected.

To participate in this trial, you need to be between 18 and 70 years old and have a single diagnosed CCM that hasn't been treated yet. Unfortunately, if you have other brain conditions or have had previous brain surgery, you wouldn’t be eligible. If you join the study, you can expect to undergo MRI scans and possibly other evaluations to help researchers gather important information about the relationship between CCMs and epilepsy. This research aims to identify new ways to manage and treat epilepsy related to these brain abnormalities.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) 18 to 70 years of age
• • (2) Diagnosed with a single cerebral cavernous malformation
• • (3) No prior treatment of the symptomatic lesion
• Exclusion Criteria:
• • (1) Associated with brain lesions and/or tumors other than CCM
• • (2) History of previous intracranial surgery
• • (3) Prior brain irradiation
• • (4) Contraindication or unwilling or unable to undergo research MRI studies
• • (5) Pregnant or breastfeeding women
• • (6) Persons unable or unlikely to return for follow-up visits
• • (7) Dementia or other progressive neurological disease